Adesso SE (ADN1)
XETRA Stock Exchange · Germany · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 72.10 |
|---|---|
| 52-week range | 47.05 – 97.70 |
| Return, 1 month / 3 months | +32.1% / +36.3% |
| Return, 1 year / 3 years | −23.6% / −15.7% |
| Trend | Uptrend |
| RSI (14) | 73 |
| Volatility (1 year) | 40.9% |
| Worst drawdown (1 year) | -48.7% |
| Average daily value traded | 0.70M EUR |
| Dividend yield | 1.1% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
adesso SE is a German information technology services company based in Dortmund. It advises clients on IT strategy and systems, develops custom software, and offers its own software products for industries such as insurance, banking, healthcare and the public sector. Its customers are mainly large organisations and public bodies that need help modernising their computer systems and digital processes. The company also provides managed services and support for the applications it builds.
On this site Adesso SE appears as a stock on the XETRA Stock Exchange (Germany), code ADN1, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Adesso SE (ADN1) trades on the XETRA Stock Exchange in Germany. It last closed at EUR 72.10 on 23 October 2026.
Its price-based Market X-Ray is 52 out of 100 (a fair price profile), ranking 361 of 701 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 23.6% and over the last three months it rose 36.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on XETRA Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 61 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 19.1% | ||
| From 52-week high | -25.8% | ||
| Momentum | 63 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 36.3% | ||
| 6-month return | 24.0% | ||
| 12-month return, skipping the last month | -42.1% | ||
| Stability (higher is calmer) | 30 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 40.9% | ||
| Worst drawdown, 1 year (smaller is calmer) | -48.7% | ||
| Liquidity | 68 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.70M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 35 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.1% | ||
| Years with dividends | 5 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Income: Dividend is small or irregular.
Returns
| 1 week | +5.7% |
|---|---|
| 1 month | +32.1% |
| 3 months | +36.3% |
| 6 months | +24.0% |
| 1 year | −23.6% |
| 3 years | −15.7% |
| 5 years | −57.5% |
Signals
| 50-day / 200-day average | 60.78 / 60.51 |
|---|---|
| Golden / death cross (60 days) | Golden, 0 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.61 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 4 Jun 2026 | EUR 0.7800 |
| 4 Jun 2025 | EUR 0.7500 |
| 5 Jun 2024 | EUR 0.7000 |
| 2 Jun 2023 | EUR 0.7000 |
| 1 Jun 2022 | EUR 0.6000 |
| 28 May 2021 | EUR 0.5200 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on XETRA Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.